CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 1,415 enrolled
Drug / intervention
Standard careprocedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02807857
NCT02807857N/ACompleted
CompareCT.gov

A Prospective Evaluation of Natriuretic Peptide Based Referral of CHF Patients in Primary Care

Novartis Pharmaceuticals·interventional·Posted Jun 21, 2016·Updated Feb 24, 2021

In Brief

A clinical study evaluating Standard care for Chronic Heart Failure (CHF). Completed, enrolled 1,415 participants across 191 sites in 18 countries.

Detailed Summary

This low interventional study, whose unique intervention was to measure the blood level of a biomarker called NT-proBNP in chronic heart failure patients daily followed-up by Primary Care Physicians (PCPs) in Europe, assessed if the cardiologist referral guided by NT-proBNP measurement in patients who were currently judged by PCPs as being stable, would lead to optimization of HF treatment, defined in adherence to treatment recommendations of the current European Society of Cardiology guidelines for the treatment of heart failure.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Heart Failure (CHF)
CountriesBelgium, Croatia, Cyprus, Denmark, Estonia, France, Hungary, Israel, Italy, Latvia, Lithuania, Malta, Norway, Poland, Portugal, Russia, Slovenia, Spain
Collaborators--

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedJun 21, 2016
Enrollment StartJul 7, 2016
Primary CompletionMar 23, 2018
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 10.0 years ago

Interventions

Standard careprocedure

Patients will receive the treatment that their primary care physician has decided to prescribe for their disease